Business Wire

CA-ALKIRA/CHECK-POINT

29.9.2021 16:12:04 CEST | Business Wire | Press release

Share
Alkira and Check Point Software Technologies Collaborate to Bring Enterprise-Class Security to Cloud Workloads

Cloud networking pioneer Alkira® and Check Point Software Technologies (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced a technology alliance to provide Check Point Software’s CloudGuard firewalls in Alkira’s Cloud Network infrastructure as-a-Service (CNaaS). This comes as organizations deploying application workloads to the cloud are struggling with the complexity of implementing consistent enterprise-wide security controls spanning cloud, multi-cloud and on-premises environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005357/en/

The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads enabling customers to deploy the same robust security in the cloud that they are used to with on-premises systems. Alkira brings a high-performance cloud network-as-a-service with global virtual infrastructure, advanced routing, intelligent service insertion and dynamic auto-scale, simplifying set-up and day 2 operations for enterprise cloud networking and security deployments.

Atif Khan, CTO and Founder of Alkira, said:
“Alkira and Check Point simplify security deployments and make it easier for enterprise customers to apply a single security posture across the entire enterprise network spanning cloud, multi-cloud and existing data center or colocation facilities. Delivering the Alkira virtual network infrastructure and Check Point security management tools as a service allows enterprises to avoid the costs and complexity of DIY solutions, and provides guaranteed performance and scalability.”

TJ Gonen, Head of Cloud Security at Check Point added :
“The combination of Check Point CloudGuard and Alkira simplifies the process of provisioning and ongoing management in the cloud networking environment which is a big win for enterprise customers. The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads, across public, hybrid and multi-cloud environments, enabling customers to benefit from a single unified security platform.”

Alkira Cloud Services Exchange® (CSX) fully automates the provisioning, licensing, service insertion, scaling and health monitoring of CloudGuard network security gateways. Alkira seamlessly inserts the CloudGuard gateways at any point in the Alkira global cloud backbone, providing stateful security controls for any on-premises, cloud, and Internet application traffic. Alkira allows customers to decouple CloudGuard from the specific cloud providers, thus providing a more efficient multi-cloud security architecture.

Cloud environments offer global presence and vast compute resources but lack the necessary routing, policy and operational controls enterprises require for a streamlined cloud firewall deployment. Even in a single cloud environment, do-it-yourself solutions result in a complex sprawl of virtual machine instances and traffic management scenarios. They also tend to make inefficient use of resources. All these problems are made worse in multi-cloud environments.

Check Point CloudGuard can be rapidly provisioned into one or multiple globally distributed Alkira Cloud Exchange Points (CXP) to provide security policy enforcement for application traffic between any set of endpoints connected to the Alkira global cloud backbone. Once CloudGuard has been provisioned within an Alkira CXP it can provide:

  • Security policy to and between public clouds
  • Cloud hosted, stateful firewall services for branches and data centers
  • Regionalized Internet breakouts for secure SaaS application access
  • Cloud DMZ environment for Internet facing applications
  • Shared cloud application services for partners and M&As

Alkira’s visual policy manager simplifies policy configuration, scoping and inspection, and streamlines auditing for assurance and compliance purposes. Alkira’s intent-based approach selectively routes traffic to firewalls according to need, improving efficiency of firewall utilization and optimizing network performance. Customers have a choice of bring-your-own license (BYOL) or pay-as-you-go (PAYG) licensing models.

Check Point offers a multilevel security architecture that defends enterprises’ cloud, network and mobile device-held information, and a comprehensive and intuitive one-point-of-control security management system.

CloudGuard is available in the Alkira network services marketplace.

For more information:

About Alkira

Alkira® delivers Cloud Networking as-a-Service (CNaaS) and developed the first Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and security services, and end-to-end visibility and governance. Alkira Cloud Services Exchange® (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira CSX is available on the AWS and Azure Marketplaces. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP and founding team member at Viptela. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet

Alkira® , Alkira Cloud Services Exchange® and Alkira Cloud Exchange Point® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/alkirainc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye